GlassScriptPhysician profile
Joseph Folz
NPI 1881013647
$5,410.36
in general payments reported to CMS, 2019-2025
32 companies · $466 in 2025
The $466 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $679 · 2021: $646 · 2022: $825 · 2023: $671 · 2024: $556 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,870.81 | 2019-2025 | Proclaim, Eterna, Octrode |
| Abbvie INC. | $664.01 | 2021-2025 | |
| Amgen INC. | $408.79 | 2019-2024 | Evenity, Prolia |
| Allergan, INC. | $194.76 | 2020-2022 | |
| Vertos Medical, INC. | $129.60 | 2020-2021 | |
| Nevro Corp. | $111.56 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $108.42 | 2022 | |
| Novartis Pharmaceuticals Corporation | $107.54 | 2020-2021 | |
| Horizon Therapeutics Plc | $82.95 | 2019-2021 | |
| Avanos Medical | $77.49 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $68.27 | 2021 | |
| Pfizer INC. | $54.74 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $52.74 | 2025 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.37 | 2019-2024 | Relistor |
| Lilly USA, LLC | $40.80 | 2021-2023 | Emgality, Reyvow |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $40.69 | 2022 | |
| Bioventus LLC | $39.23 | 2020-2023 | Gelsyn-3 |
| Medtronic, INC. | $38.13 | 2021-2025 | Intellis Adaptivestim |
| Si-Bone, INC. | $32.33 | 2020 | |
| Arbor Pharmaceuticals, INC. | $28.75 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $27.60 | 2025 | |
| Scilex Pharmaceuticals INC. | $26.53 | 2021-2022 | |
| Almatica Pharma LLC | $20.02 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.96 | 2025 | Dysport |
| Tersera Therapeutics LLC | $18.90 | 2025 | Prialt |
| Spinal Simplicity, LLC | $15.30 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.23 | 2020 | |
| Mdd US Operations, LLC | $14.66 | 2019 | |
| Boston Scientific Corporation | $13.60 | 2025 | Intracept |
| Stimwave Technologies Incorporated | $13.58 | 2020 | |
| Medtronic USA, INC. | $11.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Folz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.